Tumor Necrosis Factor-α Modulates Cerebral Aneurysm Formation and Rupture

Translational Stroke Research

Volumn 5, Issue 2, 2014, Pages 269-277

  Starke, Robert M ^a   Raper, Daniel M S ^a   Ding, Dale ^a   Chalouhi, Nohra ^b   Owens, Gary K ^a   Hasan, David M ^c   Medel, Ricky ^d   Dumont, Aaron S ^d  

^a UNIVERSITY OF VIRGINIA   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d TULANE UNIVERSITY   (United States)

Author keywords

Aneurysm; Cerebral; Inflammation; Rupture; Subarachnoid hemorrhage; TNF ; Tumor necrosis factor

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA;

AORTA ANEURYSM; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; BRAIN ARTERY ANEURYSM; BRAIN ARTERY ANEURYSM RUPTURE; HUMAN; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANEURYSM, RUPTURED; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; INTRACRANIAL ANEURYSM; OXIDATIVE STRESS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84896372316     PISSN: 18684483     EISSN: 1868601X     Source Type: Journal    
DOI: 10.1007/s12975-013-0287-9     Document Type: Article

References (71)

1. Rinkel GJ. Natural history, epidemiology and screening of unruptured intracranial aneurysms. J Neuroradiol. 2008;35(2): 99-103.
2. Komotar RJ, Zacharia BE, Mocco J, Connolly Jr ES. Controversies in the surgical treatment of ruptured intracranial aneurysms: the First Annual J. Lawrence Pool Memorial Research Symposium-controversies in the management of cerebral aneurysms. Neurosurgery. 2008;62(2): 396-407.
3. van Gijn J, Kerr RS, Rinkel GJ. Subarachnoid haemorrhage. Lancet. 2007;369(9558): 306-18.
4. Kassell NF, Torner JC. The International Cooperative Study on Timing of Aneurysm Surgery-an update. Stroke. 1984;15(3): 566-70.
5. Schievink WI. Intracranial aneurysms. N Engl J Med. 1997;336(1): 28-40.
6. Ronkainen A, Miettinen H, Karkola K, Papinaho S, Vanninen R, Puranen M, et al. Risk of harboring an unruptured intracranial aneurysm. Stroke. 1998;29(2): 359-62.
7. Nieuwkamp DJ, Setz LE, Algra A, Linn FH, de Rooij NK, Rinkel GJ. Changes in case fatality of aneurysmal subarachnoid haemorrhage over time, according to age, sex, and region: a meta-analysis. Lancet Neurol. 2009;8(7): 635-42. doi: 10. 1016/S1474-4422(09)70126-7.
8. Rosenorn J, Eskesen V, Schmidt K, Espersen JO, Haase J, Harmsen A, et al. Clinical features and outcome in 1076 patients with ruptured intracranial saccular aneurysms: a prospective consecutive study. Br J Neurosurg. 1987;1(1): 33-45.
9. Saveland H, Sonesson B, Ljunggren B, Brandt L, Uski T, Zygmunt S, et al. Outcome evaluation following subarachnoid hemorrhage. J Neurosurg. 1986;64(2): 191-6.
10. Molyneux AJ, Kerr RS, Yu LM, Clarke M, Sneade M, Yarnold JA, et al. International subarachnoid aneurysm trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised comparison of effects on survival, dependency, seizures, rebleeding, subgroups, and aneurysm occlusion. Lancet. 2005;366(9488): 809-17. doi: 10. 1016/S0140-6736(05)67214-5.
11. Wiebers DO, Whisnant JP, Huston 3rd J, Meissner I, Brown Jr RD, Piepgras DG, et al. Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment. Lancet. 2003;362(9378): 103-10.
12. Chalouhi N, Ali MS, Jabbour PM, Tjoumakaris SI, Gonzalez LF, Rosenwasser RH, et al. Biology of intracranial aneurysms: role of inflammation. J Cereb Blood Flow Metab. 2012;32(9): 1659-76. doi: 10. 1038/jcbfm. 2012. 84.
13. Kleinbongard P, Heusch G, Schulz R. TNFalpha in atherosclerosis, myocardial ischemia/reperfusion and heart failure. Pharmacol Ther. 2010;127(3): 295-314. doi: 10. 1016/j. pharmthera. 2010. 05. 002.
14. Kosierkiewicz TA, Factor SM, Dickson DW. Immunocytochemical studies of atherosclerotic lesions of cerebral berry aneurysms. J Neuropathol Exp Neurol. 1994;53(4): 399-406.
15. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ. 2003;10(1): 45-65. doi: 10. 1038/sj. cdd. 4401189.
16. Bonilla-Hernan MG, Miranda-Carus ME, Martin-Mola E. New drugs beyond biologics in rheumatoid arthritis: the kinase inhibitors. Rheumatology (Oxford). 2013;50(9): 1542-50. doi: 10. 1093/rheumatology/ker192.
17. Chen G, Goeddel DV. TNF-R1 signaling: a beautiful pathway. Science. 2002;296(5573): 1634-5. doi: 10. 1126/science. 1071924.
18. Narayan N, Lee IH, Borenstein R, Sun J, Wong R, Tong G, et al. The NAD-dependent deacetylase SIRT2 is required for programmed necrosis. Nature. 2012;492(7428): 199-204. doi: 10. 1038/nature11700.
19. Tracey KJ, Cerami A. Tumor necrosis factor, other cytokines and disease. Annu Rev Cell Biol. 1993;9: 317-43. doi: 10. 1146/annurev. cb. 09. 110193. 001533.
20. Munro JM, Pober JS, Cotran RS. Tumor necrosis factor and interferon-gamma induce distinct patterns of endothelial activation and associated leukocyte accumulation in skin of Papio anubis. Am J Pathol. 1989;135(1): 121-33.
21. Robak T, Gladalska A, Stepien H. The tumour necrosis factor family of receptors/ligands in the serum of patients with rheumatoid arthritis. Eur Cytokine Netw. 1998;9(2): 145-54.
22. Wajant H, Scheurich P. Tumor necrosis factor receptor-associated factor (TRAF) 2 and its role in TNF signaling. Int J Biochem Cell Biol. 2001;33(1): 19-32.
23. Ait-Oufella H, Taleb S, Mallat Z, Tedgui A. Recent advances on the role of cytokines in atherosclerosis. Arterioscler Thromb Vasc Biol. 2011;31(5): 969-79. doi: 10. 1161/ATVBAHA. 110. 207415.
24. Ohta H, Wada H, Niwa T, Kirii H, Iwamoto N, Fujii H, et al. Disruption of tumor necrosis factor-alpha gene diminishes the development of atherosclerosis in ApoE-deficient mice. Atherosclerosis. 2005;180(1): 11-7. doi: 10. 1016/j. atherosclerosis. 2004. 11. 016.
25. Starke RM, Chalouhi N, Ali MS, Jabbour PM, Tjoumakaris SI, Gonzalez LF, et al. The role of oxidative stress in cerebral aneurysm formation and rupture. Curr Neurovasc Res. 2013;10(3): 247-55.
26. Chalouhi N, Ali MS, Starke RM, Jabbour PM, Tjoumakaris SI, Gonzalez LF, et al. Cigarette smoke and inflammation: role in cerebral aneurysm formation and rupture. Mediat Inflamm. 2013;2012: 271582. doi: 10. 1155/2012/271582.
27. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev. 2006;86(2): 515-81. doi: 10. 1152/physrev. 00024. 2005.
28. Ali MS, Starke RM, Jabbour PM, Tjoumakaris SI, Gonzalez LF, Rosenwasser RH, et al. TNF-alpha induces phenotypic modulation in cerebral vascular smooth muscle cells: implications for cerebral aneurysm pathology. J Cereb Blood Flow Metab. 2013. doi: 10. 1038/jcbfm. 2013. 109.
29. Ali MS, Starke RM, Jabbour PM, Tjoumakaris SI, Gonzalez LF, Rosenwasser RH, et al. TNF-alpha induces phenotypic modulation in cerebral vascular smooth muscle cells: implications for cerebral aneurysm pathology. J Cereb Blood Flow Metab. 2013. doi: 10. 1038/jcbfm. 2013. 109. http://www. nature. com/jcbfm/journal/vaop/ncurrent/full/jcbfm2013109a. html.
30. Maddahi A, Kruse LS, Chen QW, Edvinsson L. The role of tumor necrosis factor-alpha and TNF-alpha receptors in cerebral arteries following cerebral ischemia in rat. J Neuroinflammation. 2011;8: 107. doi: 10. 1186/1742-2094-8-107.
31. Geng YJ, Libby P. Progression of atheroma: a struggle between death and procreation. Arterioscler Thromb Vasc Biol. 2002;22(9): 1370-80.
32. Geng YJ, Wu Q, Muszynski M, Hansson GK, Libby P. Apoptosis of vascular smooth muscle cells induced by in vitro stimulation with interferon-gamma, tumor necrosis factor-alpha, and interleukin-1 beta. Arterioscler Thromb Vasc Biol. 1996;16(1): 19-27.
33. Satoh H, Nakamura M, Satoh M, Nakajima T, Izumoto H, Maesawa C, et al. Expression and localization of tumour necrosis factor-alpha and its converting enzyme in human abdominal aortic aneurysm. Clin Sci (Lond). 2004;106(3): 301-6. doi: 10. 1042/CS20030189.
34. Xiong W, MacTaggart J, Knispel R, Worth J, Persidsky Y, Baxter BT. Blocking TNF-alpha attenuates aneurysm formation in a murine model. J Immunol. 2009;183(4): 2741-6. doi: 10. 4049/jimmunol. 0803164.
35. Skoog T, Dichtl W, Boquist S, Skoglund-Andersson C, Karpe F, Tang R, et al. Plasma tumour necrosis factor-alpha and early carotid atherosclerosis in healthy middle-aged men. Eur Heart J. 2002;23(5): 376-83. doi: 10. 1053/euhj. 2001. 2805.
36. Edvinsson LI, Povlsen GK. Vascular plasticity in cerebrovascular disorders. J Cereb Blood Flow Metab. 2011;31(7): 1554-71. doi: 10. 1038/jcbfm. 2011. 70.
37. Treska V, Topolcan O, Pecen L. Cytokines as plasma markers of abdominal aortic aneurysm. Clin Chem Lab Med. 2000;38(11): 1161-4. doi: 10. 1515/CCLM. 2000. 178.
38. Juvonen J, Surcel HM, Satta J, Teppo AM, Bloigu A, Syrjala H, et al. Elevated circulating levels of inflammatory cytokines in patients with abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol. 1997;17(11): 2843-7.
39. Hamano K, Li TS, Takahashi M, Kobayashi T, Shirasawa B, Ito H, et al. Enhanced tumor necrosis factor-alpha expression in small sized abdominal aortic aneurysms. World J Surg. 2003;27(4): 476-80. doi: 10. 1007/s00268-002-6690-0.
40. Jayaraman T, Berenstein V, Li X, Mayer J, Silane M, Shin YS, et al. Tumor necrosis factor alpha is a key modulator of inflammation in cerebral aneurysms. Neurosurgery. 2005;57(3): 558-64. discussion -64.
41. Jayaraman T, Paget A, Shin YS, Li X, Mayer J, Chaudhry H, et al. TNF-alpha-mediated inflammation in cerebral aneurysms: a potential link to growth and rupture. Vasc Health Risk Manag. 2008;4(4): 805-17.
42. Aoki T, Kataoka H, Ishibashi R, Nozaki K, Egashira K, Hashimoto N. Impact of monocyte chemoattractant protein-1 deficiency on cerebral aneurysm formation. Stroke. 2009;40(3): 942-51. doi: 10. 1161/STROKEAHA. 108. 532556.
43. Kanematsu Y, Kanematsu M, Kurihara C, Tada Y, Tsou TL, van Rooijen N, et al. Critical roles of macrophages in the formation of intracranial aneurysm. Stroke. 2010;42(1): 173-8. doi: 10. 1161/STROKEAHA. 110. 590976.
44. Paolisso G, Rizzo MR, Mazziotti G, Tagliamonte MR, Gambardella A, Rotondi M, et al. Advancing age and insulin resistance: role of plasma tumor necrosis factor-alpha. Am J Physiol. 1998;275(2 Pt 1): E294-9.
45. Kirwan JP, Krishnan RK, Weaver JA, Del Aguila LF, Evans WJ. Human aging is associated with altered TNF-alpha production during hyperglycemia and hyperinsulinemia. Am J Physiol Endocrinol Metab. 2001;281(6): E1137-43.
46. Anto RJ, Mukhopadhyay A, Shishodia S, Gairola CG, Aggarwal BB. Cigarette smoke condensate activates nuclear transcription factor-kappaB through phosphorylation and degradation of IkappaB(alpha): correlation with induction of cyclooxygenase-2. Carcinogenesis. 2002;23(9): 1511-8.
47. Starke RM, Ali MS, Jabbour PM, Tjoumakaris SI, Gonzalez F, Hasan DM, et al. Cigarette smoke modulates vascular smooth muscle phenotype: implications for carotid and cerebrovascular disease. PLoS One. 2013;8(8): e71954. doi: 10. 1371/journal. pone. 0071954.
48. Sun SH, Tang WX, Liu C, Lin H, Yang HH. Effects of tumor necrosis factor alpha on proteolysis of respiratory muscles in rats with chronic obstructive pulmonary disease. Zhonghua Jie He He Hu Xi Za Zhi. 2007;30(3): 186-91.
49. Lanzke N, Kleinwachter R, Kerschischnik S, Sargsyan L, Groneberg DA, Kamradt T, et al. Differential effects of ethanol on IFN-gamma- and TNF-alpha-producing splenic T lymphocytes in a murine model of gram-negative pneumonia. Addict Biol. 2007;12(1): 59-68. doi: 10. 1111/j. 1369-1600. 2006. 00042. x.
50. Beeftink MM, Ruigrok YM, Rinkel GJ, van den Bergh WM. Relation of serum TNF-alpha and TNF-alpha genotype with delayed cerebral ischemia and outcome in subarachnoid hemorrhage. Neurocrit Care. 2011;15(3): 405-9. doi: 10. 1007/s12028-011-9556-1.
51. Frosen J, Piippo A, Paetau A, Kangasniemi M, Niemela M, Hernesniemi J, et al. Remodeling of saccular cerebral artery aneurysm wall is associated with rupture: histological analysis of 24 unruptured and 42 ruptured cases. Stroke. 2004;35(10): 2287-93. doi: 10. 1161/01. STR. 0000140636. 30204. da.
52. Nuki Y, Matsumoto MM, Tsang E, Young WL, van Rooijen N, Kurihara C, et al. Roles of macrophages in flow-induced outward vascular remodeling. J Cereb Blood Flow Metab. 2009;29(3): 495-503. doi: 10. 1038/jcbfm. 2008. 136.
53. Hingorani A, Ascher E, Scheinman M, Yorkovich W, DePippo P, Ladoulis CT, et al. The effect of tumor necrosis factor binding protein and interleukin-1 receptor antagonist on the development of abdominal aortic aneurysms in a rat model. J Vasc Surg. 1998;28(3): 522-6.
54. Kaneko H, Anzai T, Horiuchi K, Kohno T, Nagai T, Anzai A, et al. Tumor necrosis factor-alpha converting enzyme is a key mediator of abdominal aortic aneurysm development. Atherosclerosis. 2011;218(2): 470-8. doi: 10. 1016/j. atherosclerosis. 2011. 06. 008.
55. Nuki Y, Tsou TL, Kurihara C, Kanematsu M, Kanematsu Y, Hashimoto T. Elastase-induced intracranial aneurysms in hypertensive mice. Hypertension. 2009;54(6): 1337-44. doi: 10. 1161/HYPERTENSIONAHA. 109. 138297.
56. Fontanella M, Rainero I, Gallone S, Rubino E, Fenoglio P, Valfre W, et al. Tumor necrosis factor-alpha gene and cerebral aneurysms. Neurosurgery. 2007;60(4): 668-72. doi: 10. 1227/01. NEU. 0000255417. 93678. 49. discussion 72-3.
57. Kondo S, Hashimoto N, Kikuchi H, Hazama F, Nagata I, Kataoka H. Apoptosis of medial smooth muscle cells in the development of saccular cerebral aneurysms in rats. Stroke. 1998;29(1): 181-8. discussion 9.
58. Hara A, Yoshimi N, Mori H. Evidence for apoptosis in human intracranial aneurysms. Neurol Res. 1998;20(2): 127-30.
59. Jayaraman T, Marks AR. Calcineurin is downstream of the inositol 1, 4, 5-trisphosphate receptor in the apoptotic and cell growth pathways. J Biol Chem. 2000;275(9): 6417-20.
60. Hanafy KA, Grobelny B, Fernandez L, Kurtz P, Connolly ES, Mayer SA, et al. Brain interstitial fluid TNF-alpha after subarachnoid hemorrhage. J Neurol Sci. 2010;291(1-2): 69-73. doi: 10. 1016/j. jns. 2009. 12. 023.
61. Moravan M, Segal BM. Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil. Neurology. 2009;72(4): 337-40. doi: 10. 1212/01. wnl. 0000341278. 26993. 22.
62. Andreadou E, Kemanetzoglou E, Brokalaki C, Evangelopoulos ME, Kilidireas C, Rombos A, et al. Demyelinating disease following anti-TNFa treatment: a causal or coincidental association? Report of four cases and review of the literature. Case Rep Neurol Med. 2013;2013: 671935. doi: 10. 1155/2013/671935.
63. Pardo CA, Buckley A, Thurm A, Lee LC, Azhagiri A, Neville DM, et al. A pilot open-label trial of minocycline in patients with autism and regressive features. J Neurodev Disord. 2013;5(1): 9. doi: 10. 1186/1866-1955-5-9.
64. Wang DD, Englot DJ, Garcia PA, Lawton MT, Young WL. Minocycline- and tetracycline-class antibiotics are protective against partial seizures in vivo. Epilepsy Behav. 2012;24(3): 314-8. doi: 10. 1016/j. yebeh. 2012. 03. 035.
65. Dean OM, Data-Franco J, Giorlando F, Berk M. Minocycline: therapeutic potential in psychiatry. CNS Drugs. 2012;26(5): 391-401. doi: 10. 2165/11632000-000000000-00000.
66. Chen X, Ma X, Jiang Y, Pi R, Liu Y, Ma L. The prospects of minocycline in multiple sclerosis. J Neuroimmunol. 2011;235(1-2): 1-8. doi: 10. 1016/j. jneuroim. 2011. 04. 006.
67. Siciliano G, Carlesi C, Pasquali L, Piazza S, Pietracupa S, Fornai F, et al. Clinical trials for neuroprotection in ALS. CNS Neurol Disord Drug Targets. 2010;9(3): 305-13.
68. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neurology. 1999;53(3): 457-65.
69. Tomas-Camardiel M, Rite I, Herrera AJ, de Pablos RM, Cano J, Machado A, et al. Minocycline reduces the lipopolysaccharide-induced inflammatory reaction, peroxynitrite-mediated nitration of proteins, disruption of the blood-brain barrier, and damage in the nigral dopaminergic system. Neurobiol Dis. 2004;16(1): 190-201. doi: 10. 1016/j. nbd. 2004. 01. 010.
70. Tobinick E, Gross H, Weinberger A, Cohen H. TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study. MedGenMed. 2006;8(2): 25.
71. Faustman D, Davis M. TNF receptor 2 pathway: drug target for autoimmune diseases. Nat Rev Drug Discov. 2010;9(6): 482-93. doi: 10. 1038/nrd3030.